导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.74% | 1747/4773 |
| 近一周 | -3.17% | 3780/5458 |
| 近一月 | -8.97% | 4561/5421 |
| 近一季 | -13.67% | 4541/5205 |
| 近半年 | -0.35% | 1498/4920 |
| 近一年 | 8.76% | 1260/4361 |
| 近两年 | 110.92% | 486/2954 |
| 近三年 | 64.62% | 384/2253 |
| 成立以来 | 84.23% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.69% 1911/4961 |
35.04% 929/5312 |
- - |
- - |
| 2025 | 48.36% 530/4813 |
-1.64% 2724/3635 |
3.17% 1128/4076 |
47.56% 451/4524 |
-0.92% 2719/4813 |
| 2024 | 14.53% 1038/3463 |
-3.67% 1539/2808 |
-6.36% 1924/3014 |
27.83% 205/3129 |
-0.67% 1494/3463 |
| 2023 | -18.06% 1780/2656 |
2.19% 1413/2280 |
-6.94% 1745/2385 |
-8.96% 1755/2515 |
-5.36% 1330/2655 |
| 2022 | -28.06% 1522/2207 |
-19.08% 1427/1919 |
5.49% 891/2016 |
-17.64% 1626/2113 |
2.34% 969/2208 |
| 2021 | 12.06% 389/1822 |
-6.46% 1004/1255 |
25.15% 97/1330 |
-6.35% 920/1466 |
2.23% 652/1822 |
| 2020 | 63.24% 108/1250 |
4.17% 84/1028 |
28.67% 96/1067 |
6.16% 869/1164 |
14.73% 253/1184 |
| 2019 | 41.78% 229/1092 |
33.41% 135/739 |
-9.76% 688/788 |
7.28% 96/850 |
9.78% 194/918 |
| 2018 | -26.62% 389/834 |
- - |
-14.39% 490/631 |
-11.29% 574/660 |
-10.69% 215/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方创业板ETF联接C VS. 长安沪深300非周期A(740101) |